Podocyturia is significantly elevated in untreated vs treated Fabry adult patients

Journal of Nephrology

Volumn 29, Issue 6, 2016, Pages 791-797

  Trimarchi, Hernán ^a   Canzonieri, Romina ^a   Schiel, Amalia ^a   Politei, Juan ^b   Stern, Aníbal ^a   Andrews, José ^a   Paulero, Matías ^a   Rengel, Tatiana ^a   Aráoz, Alicia ^c   Forrester, Mariano ^a   Lombi, Fernando ^a   Pomeranz, Vanesa ^a   Iriarte, Romina ^a   Young, Pablo ^a   Muryan, Alexis ^a   Zotta, Elsa ^c  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b Fundación para el Estudio de Enfermedades Neurometabólicas   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Fabry disease; Podocyte; Podocyturia; proteinuria; galactosidase

Indexed keywords

ALPHA GALACTOSIDASE; BIOLOGICAL MARKER; CREATININE; ENALAPRIL; SYNAPTOPODIN; VALSARTAN; AGALSIDASE BETA; ISOENZYME;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; ENZYME THERAPY; ESTIMATED GLOMERULAR FILTRATION RATE; FABRY DISEASE; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PODOCYTE; PODOCYTURIA; PROTEINURIA; RENAL PROTECTION; ADOLESCENT; CASE CONTROL STUDY; COMPLICATION; CYTOLOGY; DRUG EFFECTS; ENZYME REPLACEMENT; MIDDLE AGED; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; URINALYSIS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; BIOMARKERS; CASE-CONTROL STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PODOCYTES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINALYSIS; URINE; YOUNG ADULT;

EID: 84992448491     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-016-0271-z     Document Type: Article

References (40)

1. Desnick RJ, Ioannou Y, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
2. Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137–148
3. Warnock DJ (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hyperten 14:87–95
4. Trimarchi H, Forrester M, Lombi F et al (2014) Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease. The potential roles of plasmin and uPAR. Case Reports in Nephrology 1–6: ID 854521
5. Ortiz A, Oliveira JP, Waldek S et al (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607
6. Najafian B, Svarstad E, Bostad L et al (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79:663–670
7. Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138
8. Tsakiris D, Simpson HK, Jones EH et al (1996) Report on management of renal failure in Europe-XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11:4–20
9. Thadhani R, Wolf M, West ML et al (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249–255
10. Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 64:801–807
11. Kotanko P, Kramar R, Devrnja D et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323–1329
12. Trimarchi H, Canzonieri R, Muryan A, et al (2015) Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Reports in Nephrology 257628
13. Takahashi N, Yokoi S, Kasuno K (2015) A heterogeneous female with Fabry disease due to a nivel alpha-galactosidase A mutation exhibits a ubnique synaptopodin distributin in vacuolated podocytes. Clin Nephrol 3:301–308
14. Anasuma K, Kim K, Oh J et al (2005) Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest 115:1188–1198
15. Ichimura K, Kurihara H, Sakai T (2003) Actin filament organization of foot process in rat podocytes. J Histochem Cytochem 51:1589–1600
16. Greka A, Mundel P (2012) Cell biology and pathology of podocytes. Annu Rev Physiol 74:299–323
17. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S et al (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931–938
18. Smoyer WE, Mundel P, Gupta E et al (1997) Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am J Physiol 273 Renal Physiol 42:F150–F157
19. Vogelmann SU, Nelson WJ, Myers BD et al (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285:F40–F48
20. Fornoni A, Merscher S, Kopp JB (2014) Lipid biology of podocyte-new perspectives offer new opportunities. Nat Rev Nephrol 10:379–388
21. Wharram BL, Goyal M, Wiggins JE et al (2005) Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941–2952
22. Trimarchi H (2015) Podocyturia. What is in a name? J Translat Internal Med 3:51–56
23. Jim B, Jean-Louis P, Qipo A et al (2012) Podocyturia as a diagnostic marker of preeclampsia amongst high-risk pregnant patients. J of Pregnancy ID 984630. doi:10.1155/2012/984630
24. Rodrigues Pereira S, Castro Teixeira V, Nishida SK (2013) Detection of podocyturia in patients with lupus nephritis. J Brasil Nefrol 35:252–258
25. Maestroni S, Maestroni A, Dell’Antonio G et al (2014) Viable podocyturia in healthy individuals: implications for podocytopathies. Am J Kidney Dis 64:1003–1005
26. Mauer M, Glynn E, Svarstad E et al (2014) Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. Plos One 9:e112188
27. Germain DP, Charrow J, Desnick RJ et al (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52:353–358
28. Gaggl M, Hofer M, Weidner S et al (2015) Interfering parameters in the determination of urinary globotriasocylceramide (Gb3) in patients with chronic kidney disease. J Nephrol 6:679–689
29. 3) in patients with Fabry disease. Clin Chimica Acta 279:55–68
30. Trimarchi H (2015) Plasmin, urokinase plasminogen activator receptor and amiloride in the nephrotic syndrome. In: Nephrotic syndrome. Etiology, pathogenesis and pathology. Mubarak M (ed) Nova Biomedical, New York
31. Chapman HA, Wei Y (2001) Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 86:124–129
32. Wei C, Möller CC, Altintas MM et al (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55–63
33. Regoli M, Bendayan M (1997) Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia 40:15–22
34. Sachs N, Sonnenberg A (2013) Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 9:200–210
35. Sanchez-Niño MD, Sanz AB, Carrasco S et al (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26:1797–1802
36. Liebau MC, Braun F, Höpker K et al (2013) Dysregulated autophagy contributes to podocyte damage in Fabry’s disease. PLoS One 8:e63506
37. Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A (2015) Lyso-GB3 activates Notch 1 in humaan podocytes. Hum Mol Genet 24(20):5720–5734
38. Müller-Deile J, Schiffer M (2015) Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? Pediatr Nephrol. doi:10.1007/s00467-015-3116-4
39. Mundel P, Gilbert P, Kriz W (1991) Podocytes in glomerulus of rat kidney express a characteristic 44 KD protein. J Histochem Cytochem 39(8):1047–1056
40. Nakamura T, Ushiyama C, Suzuki S et al (2000) Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15:1379–1383